Jeffrey Jones, MD, discusses treatment options for patients with chronic lymphocytic leukemia (CLL) who progress on, or become intolerant of, idelalisib or ibrutinib during their treatment.
Jeffrey Jones, MD, assistant professor of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia (CLL) who progress on, or become intolerant of, idelalisib or ibrutinib during their treatment. Jones says one option is to begin salvage treatment with either idelalisib or ibrutinib after one of the two treatment options fails. Utilizing the treatment option not initially chosen has resulted in about a 50% response rate.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
FDA Enforces Partial Hold on Trial of Seclidemstat in MDS/CMML
July 16th 2024Following the report of a serious and unexpected grade 4 adverse effect, a partial clinical hold has been placed on the phase 1 trial evaluating seclidemstat with azacitidine in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Read More